Repligen Q3-26 Earnings Call - REPLIGEN CORP

Explicit Guidance:

• Full-Year 2026 Revenue: Raised to $844–$852 million (midpoint $848 million), representing 14.5–15.5% reported growth (12–13% organic).
  • Assumes $24 million revenue contribution from BioLife (post-closing Oct 6, 2026).
  • Assumes neutral foreign currency (previously a tailwind).
  • Assumes ~1% headwind from PolyMem divestiture.
• Full-Year 2026 Organic Growth: Narrowed to 12–13% (midpoint increase of 50 bps vs. prior).
• Full-Year 2026 Gross Margin: Expected expansion of 110–160 basis points, likely landing above the midpoint due to BioLife inclusion.
• Full-Year 2026 Operating Margin: Raised to 16.0–16.3% (range of $135–$139 million operating income), representing 220–250 bps expansion.
• Full-Year 2026 EPS: Adjusted fully diluted EPS of $2.05–$2.29 (midpoint up 21% YoY).
• Q4 2026 Specifics: Assumes organic growth within the full-year range; operating expenses expected to rise low double-digit millions sequentially due to a nearly full quarter of BioLife expenses and base business investments.
• Capital Expenditures (CapEx): Expected to remain 3–4% of 2026 revenue.

Business-Segment Outlook:

• Filtration: Expected to be flat to slightly down for 2026 due to timing of system orders shifting to 2027 and PolyMem divestiture; revenue recognition for current backlog is scheduled for 2027.
• Chromatography: Expected to grow >30% for 2026, driven by continuous growth in OPUS columns and large-scale columns.
• Proteins: Expected to grow mid-teens for 2026, with YTD growth of 34%; driven by ligands, growth factors, and custom/catalog resins.
• Analytics: Expected to grow >30% for 2026; driven by consumables, services, and adoption of USP Chapter 507-validated Solo VP Plus and Flow VPX technologies.
• Services: YTD systems under contract increased nearly 40%; expected to become a larger revenue mix moving forward.
• BioLife Acquisition (Cell Therapy): Integrated revenue of $24 million in Q4 2026; full-year 2026 revenue contribution modeled at ~$114 million (pro forma).
• 2027 Outlook (Strategic Targets): Reported top-line growth of at least 25% (assuming high-single-digit market growth), potentially exceeding $1 billion in revenue; assumes neutral FX.
• 2027 Margin & EPS: BioLife expected to provide >5 cents of year-one EPS accretion in 2027; long-term goal to achieve 30% EBITA margin by 2030, potentially accelerated by BioLife integration.

Market and Competitive Outlook:

• Capital Equipment Demand: Orders for systems reached a 5-year high in Q3 2026, building a backlog for 2027; revenue recognition delayed to 2027, but management views the "tap" as only 5–10% open relative to potential.
• End-Market Trends: Biopharma revenue driving growth across all regions; Emerging Biotech growing high single digits (YTD high teens); Cell Therapy growing >25% (excluding gene therapy headwind); Gene therapy growing >25% on an absolute basis.
• Onshoring: Management sees potential for significant onshoring demand over the next few years, with RFP wins increasing (3 in Q3); expects orders and deliveries to materialize primarily in 2027 and 2028.
• Biosimilars: Anticipated inflection point for biosimilar-driven demand over the next 2–3 years as patent cliffs approach for products like Keytruda; new product wins accelerating in Q3.
• China Market: Government's 5-year plan targets >20% CAGR for biotech through 2030; Repligen expects China to be the fastest-growing biopharma market; Q3 revenue growth in China was >40% (YTD >50%).

Macro / Industry Outlook:

• Market Growth Assumptions: Assumes industry market growth of high single digits for 2026 and 2027; aims to outpace market by >500 bps annually.
• Foreign Exchange: Assuming neutral FX for 2026 guidance; neutral FX assumed for 2027 growth calculations.
• Interest Rates: Favorable interest income trends due to rising rates offset by cash deployed for BioLife; adjusted tax rate assumed at 22%.
• Regulatory: USP Chapter 507 recognition of Solo VP Plus technology expected to reduce adoption barriers and validate technology with regulators.
• Supply Chain/Inflation: Inflationary pressures on product mix and costs are partially offset by price execution, volume leverage, and IT/AI-driven productivity.

Strategic Initiatives:

• BioLife Integration: Focus on capturing >50% of anticipated year-one operating expense synergies (public company/leadership costs) and improving cryo-store scrap rates; revenue synergies via cross-trained commercial teams.
• Asia-Pacific Expansion: Opened new training and innovation center in South Korea; advancing technology transfers with OEM partners in China to recapture market share.
• IT & AI Modernization: Hiring of new CIO; deploying AI pilots for intelligent inspections and manufacturing automation to offset inflation and drive productivity; "Fit for Growth" transformation office active.
• Product Innovation: Expanded supply agreement with Ecolab; integrated solution team focused on customer capacity expansion projects.
• Investment Strategy: Planning to reinvest margin benefits (potentially earlier than 2030 30% EBITA target) into additional commercial resources and R&D to accelerate revenue growth.

Risks and Headwinds to Outlook:

• Revenue Timing: Significant capital equipment revenue recognition deferred to 2027; current backlog not recognized in 2026.
• Integration Uncertainty: BioLife revenue in Q4 2026 modeled at $24 million based on specific shipment timing; full 2027 financial impact dependent on finalizing budget and integration progress.
• Customer Decision Velocity: Customer project delays and slow "push button" order decision-making persist despite high funnel and order intake.
• Regulatory Approvals: FDA approvals for new cell therapies and biosimilars are viewed as swing factors for 2027 market growth.
• FX Volatility: Material changes in foreign exchange rates could impact reported growth and top-line targets.
• Inflation: Continued inflationary pressure on costs and product mix could impact margins if not offset by productivity gains.

Management Tone on the Future:

• Confidence Level: Highly confident in the "next phase of growth," citing record quarter, strong backlog, and successful integration progress.
• Strategic Outlook: Management expresses excitement about expanding capabilities in cell therapy and views the company as "extremely well-positioned" to outpace the market.
• Milestones: Anticipates reaching $1 billion in revenue in 2027 as a significant milestone.
• Change in Guidance: Repeatedly emphasizes "increasing guidance" multiple times, reflecting strong execution and successful deal model realization.
• Hedges: Notes "prudent approach" to initial assumptions; acknowledges the "tap" for capital equipment has not fully opened yet.

Miscellaneous:

• GAAP vs. Non-GAAP: Q3 GAAP results included a $41 million one-time intangible asset impairment charge, excluded from adjusted results.
• Cash Position: Ended Q3 2026 with $863 million in cash/securities; pro forma cash balance post-BioLife deal is > $300 million.
• Divestitures: PolyMem divestiture noted as a ~1% headwind to 2026 growth.
• Acquisition Details: BioLife deal closed October 6, 2026; $550 million cash deployed (net of fees and cash received).